Glenmark Life Sciences Limited

BSE:543322 Stock Report

Market Cap: ₹132.3b

Glenmark Life Sciences Valuation

Is 543322 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543322 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 543322 (₹1081.15) is trading above our estimate of fair value (₹542.95)

Significantly Below Fair Value: 543322 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543322?

Key metric: As 543322 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543322. This is calculated by dividing 543322's market cap by their current earnings.
What is 543322's PE Ratio?
PE Ratio31.2x
Earnings₹4.24b
Market Cap₹132.34b

Price to Earnings Ratio vs Peers

How does 543322's PE Ratio compare to its peers?

The above table shows the PE ratio for 543322 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average67x
532482 Granules India
27.1x22.1%₹132.2b
STAR Strides Pharma Science
78.1x45.6%₹138.3b
500674 Sanofi India
26.4x-2.6%₹140.1b
AETHER Aether Industries
136.3x44.8%₹110.1b
543322 Glenmark Life Sciences
31.2x23.4%₹132.3b

Price-To-Earnings vs Peers: 543322 is good value based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (67x).

Price to Earnings Ratio vs Industry

How does 543322's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
543322 31.2xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 543322 is good value based on its Price-To-Earnings Ratio (31.2x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is 543322's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543322 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio41.3x

Price-To-Earnings vs Fair Ratio: 543322 is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (41.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 543322 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,081.15
₹1,138.60
+5.3%
9.2%₹1,295.00₹1,015.00n/a5
Nov ’25₹1,053.55
₹1,080.50
+2.6%
14.9%₹1,295.00₹790.00n/a6
Oct ’25₹1,124.05
₹1,084.33
-3.5%
16.0%₹1,295.00₹790.00n/a6
Sep ’25₹1,057.25
₹1,031.83
-2.4%
15.3%₹1,295.00₹790.00n/a6
Aug ’25₹902.30
₹989.33
+9.6%
10.9%₹1,150.00₹790.00n/a6
Jul ’25₹886.80
₹932.60
+5.2%
9.2%₹1,040.00₹790.00n/a5
Jun ’25₹834.55
₹932.60
+11.7%
9.2%₹1,040.00₹790.00n/a5
May ’25₹829.10
₹932.60
+12.5%
9.2%₹1,040.00₹790.00n/a5
Apr ’25₹784.75
₹874.67
+11.5%
8.9%₹940.00₹765.00n/a3
Mar ’25₹858.80
₹874.67
+1.8%
8.9%₹940.00₹765.00n/a3
Feb ’25₹852.70
₹874.67
+2.6%
8.9%₹940.00₹765.00n/a3
Jan ’25₹655.85
₹685.00
+4.4%
6.7%₹720.00₹620.00n/a3
Dec ’24₹636.40
₹685.00
+7.6%
6.7%₹720.00₹620.00n/a3
Nov ’24₹619.55
₹685.00
+10.6%
6.7%₹720.00₹620.00₹1,053.553
Oct ’24₹617.55
₹707.75
+14.6%
7.5%₹756.00₹620.00₹1,124.054
Sep ’24₹632.70
₹708.20
+11.9%
6.7%₹756.00₹620.00₹1,057.255
Aug ’24₹638.60
₹708.20
+10.9%
6.7%₹756.00₹620.00₹902.305
Jul ’24₹569.40
₹603.00
+5.9%
8.9%₹685.00₹525.00₹886.805
Jun ’24₹542.10
₹603.00
+11.2%
8.9%₹685.00₹525.00₹834.555
May ’24₹504.10
₹586.80
+16.4%
6.0%₹630.00₹525.00₹829.105
Apr ’24₹391.60
₹551.00
+40.7%
8.5%₹604.00₹485.00₹784.754
Mar ’24₹375.45
₹551.00
+46.8%
8.5%₹604.00₹485.00₹858.804
Feb ’24₹379.90
₹551.00
+45.0%
8.5%₹604.00₹485.00₹852.704
Jan ’24₹420.45
₹562.25
+33.7%
7.2%₹629.00₹525.00₹655.854
Dec ’23₹432.95
₹562.25
+29.9%
7.2%₹629.00₹525.00₹636.404
Nov ’23₹437.50
₹562.25
+28.5%
7.2%₹629.00₹525.00₹619.554

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

7D

-0.4%

1Y

58.1%